Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Dobinson, Hazel C.; Gibani, Malick M.; Jones, Claire; Thomaides-Brears, Helena B.; Voysey, Merryn; Darton, Thomas C.; Waddington, Claire S.; Campbell, Danielle; Milligan, Iain; Zhou, Liqing; Shrestha, Sonu; Kerridge, Simon A.; Peters, Anna; Stevens, Zoe; Podda, Audino; Martin, Laura B.; D?Alessio, Flavia; Thanh, Duy Pham; Basnyat, Buddha; Baker, Stephen; Angus, Brian; Levine, Myron M.; Blohmke, Christoph J.; Pollard, Andrew J. (2017)
Publisher: Oxford University Press
Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Languages: English
Types: Article
Subjects: enteric fever, Salmonella enterica paratyphi A, Major Article, paratyphoid infection, human challenge study, Editor's Choice, immune responses
Background.\ud \ud To expedite the evaluation of vaccines against paratyphoid fever, we aimed to develop the first human challenge model of Salmonella enterica serovar Paratyphi A infection.\ud Methods.\ud \ud Two groups of 20 participants underwent oral challenge with S. Paratyphi A following sodium bicarbonate pretreatment at 1 of 2 dose levels (group 1: 1–5 × 103 colony-forming units [CFU] and group 2: 0.5–1 × 103 CFU). Participants were monitored in an outpatient setting with daily clinical review and collection of blood and stool cultures. Antibiotic treatment was started when prespecified diagnostic criteria were met (temperature ≥38°C for ≥12 hours and/or bacteremia) or at day 14 postchallenge.\ud Results.\ud \ud The primary study objective was achieved following challenge with 1–5 × 103 CFU (group 1), which resulted in an attack rate of 12 of 20 (60%). Compared with typhoid challenge, paratyphoid was notable for high rates of subclinical bacteremia (at this dose, 11/20 [55%]). Despite limited symptoms, bacteremia persisted for up to 96 hours after antibiotic treatment (median duration of bacteremia, 53 hours [interquartile range, 24–85 hours]). Shedding of S. Paratyphi A in stool typically preceded onset of bacteremia.\ud Conclusions.\ud \ud Challenge with S. Paratyphi A at a dose of 1–5 × 103 CFU was well tolerated and associated with an acceptable safety profile. The frequency and persistence of bacteremia in the absence of clinical symptoms was notable, and markedly different from that seen in previous typhoid challenge studies. We conclude that the paratyphoid challenge model is suitable for the assessment of vaccine efficacy using endpoints that include bacteremia and/or symptomatology.\ud Clinical Trials Registration.\ud \ud NCT02100397.

Share - Bookmark

Funded by projects

  • WT | Acceleration of the Developm...

Cite this article